Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Intermediate dose intravenous melphalan at a dose of 15 mg/m2 x 4 given at 21-day intervals has been evaluated in 20 consecutive patients. The aims were to assess the time to obtain maximal response, duration of response and response to reintroduction of intravenous melphalan on relapse. Median time to maximal response was 17 weeks. Four patients achieved a complete response with complete disappearance of paraprotein. On relapse, reintroduction of intravenous melphalan was unsuccessful in causing a reduction of paraprotein, suggesting that resistance to this dose of melphalan occurs early even in responding patients.

Original publication




Journal article


Acta Haematol

Publication Date





233 - 238


Drug Evaluation, Drug Resistance, Humans, Injections, Intravenous, Melphalan, Multiple Myeloma, Myeloma Proteins